Lin Y Chen1, J Thomas Bigger2, Kathleen T Hickey2,3, Haiying Chen4, Carlos Lopez-Jimenez2, Mary Ann Banerji5, Gregory Evans4, Jerome L Fleg6, Vasilios Papademetriou7, Abraham Thomas8, Vincent Woo9, Elizabeth R Seaquist10, Elsayed Z Soliman11,12. 1. Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA. 2. Columbia University Department of Medicine, Division of Cardiology, New York, New York, USA. 3. Columbia University School of Nursing, New York, New York, USA. 4. Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. 5. SUNY Downstate Medical Center, Brooklyn, New York, USA. 6. Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA. 7. The Veterans Administration Medical Center, Washington, DC, USA. 8. Endocrinology, Diabetes, Bone and Mineral Disorders Division, Henry Ford Hospital, Detroit, Michigan, USA. 9. Section of Endocrinology and Metabolism, University of Manitoba, Winnipeg, Manitoba, Canada. 10. Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA. 11. Epidemiological Cardiology Research Center (EPICARE), Department of Epidemiology and Prevention, Division of Public Health Sciences, Winston-Salem, North Carolina, USA. 12. Department of Medicine, Section on Cardiology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Abstract
BACKGROUND: There are no proven strategies to prevent atrial fibrillation (AF) in patients with type 2 diabetes (T2DM). We compared standard blood pressure (BP) lowering vs. intensive BP lowering in reducing incidence of AF or P-wave indices (PWI-ECG markers of left atrial abnormality that are considered intermediate phenotypes of AF) in patients with T2DM. METHODS: We analyzed data from the ACCORD BP trial-a randomized controlled nonblinded trial (2001-2009) which randomized patients with T2DM and systolic BP (SBP) 130-180mm Hg on ≤3 antihypertensive medications aged 40-79 years with cardiovascular disease (CVD) or aged 55-79 years with subclinical CVD or ≥2 CVD risk factors to standard BP lowering (SBP <140mm Hg) vs. intensive BP lowering (SBP <120mm Hg). The primary outcome was a composite of incident AF and PWI. RESULTS: Data from 3,087 participants (mean age, 62.2 years; women, 48.2%; non-White, 39.2%) were analyzed. During a mean follow-up of 4.4 years, the primary outcome occurred in 1,063 participants (incidence rate, 84.5 per 1,000 person-years in the standard-therapy group vs. 73.9 per 1,000 person-years in the intensive-therapy group). The adjusted hazard ratios (95% confidence intervals) of intensive-therapy group for the primary outcome and for incident PWI alone were 0.87 (0.77-0.98), P = 0.02 and 0.87 (0.76-0.98), P = 0.02, respectively. The effect of intensive therapy on the incidence of AF alone did not reach statistical significance. CONCLUSIONS: In patients with T2DM, intensive BP lowering reduces the incidence of the composite outcome of AF and PWI, suggesting a potential benefit from stringent BP control in patients with T2DM. clinical trials registration Trial Number NCT00000620.
RCT Entities:
BACKGROUND: There are no proven strategies to prevent atrial fibrillation (AF) in patients with type 2 diabetes (T2DM). We compared standard blood pressure (BP) lowering vs. intensive BP lowering in reducing incidence of AF or P-wave indices (PWI-ECG markers of left atrial abnormality that are considered intermediate phenotypes of AF) in patients with T2DM. METHODS: We analyzed data from the ACCORD BP trial-a randomized controlled nonblinded trial (2001-2009) which randomized patients with T2DM and systolic BP (SBP) 130-180mm Hg on ≤3 antihypertensive medications aged 40-79 years with cardiovascular disease (CVD) or aged 55-79 years with subclinical CVD or ≥2 CVD risk factors to standard BP lowering (SBP <140mm Hg) vs. intensive BP lowering (SBP <120mm Hg). The primary outcome was a composite of incident AF and PWI. RESULTS: Data from 3,087 participants (mean age, 62.2 years; women, 48.2%; non-White, 39.2%) were analyzed. During a mean follow-up of 4.4 years, the primary outcome occurred in 1,063 participants (incidence rate, 84.5 per 1,000 person-years in the standard-therapy group vs. 73.9 per 1,000 person-years in the intensive-therapy group). The adjusted hazard ratios (95% confidence intervals) of intensive-therapy group for the primary outcome and for incident PWI alone were 0.87 (0.77-0.98), P = 0.02 and 0.87 (0.76-0.98), P = 0.02, respectively. The effect of intensive therapy on the incidence of AF alone did not reach statistical significance. CONCLUSIONS: In patients with T2DM, intensive BP lowering reduces the incidence of the composite outcome of AF and PWI, suggesting a potential benefit from stringent BP control in patients with T2DM. clinical trials registration Trial Number NCT00000620.
Authors: Yoko Miyasaka; Marion E Barnes; Bernard J Gersh; Stephen S Cha; Kent R Bailey; Walter P Abhayaratna; James B Seward; Teresa S M Tsang Journal: Circulation Date: 2006-07-03 Impact factor: 29.690
Authors: Rachel R Huxley; Faye L Lopez; Aaron R Folsom; Sunil K Agarwal; Laura R Loehr; Elsayed Z Soliman; Rich Maclehose; Suma Konety; Alvaro Alonso Journal: Circulation Date: 2011-03-28 Impact factor: 29.690
Authors: William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi Journal: N Engl J Med Date: 2010-03-14 Impact factor: 91.245
Authors: G K Andrikopoulos; P E Dilaveris; D J Richter; E J Gialafos; A G Synetos; J E Gialafos Journal: Pacing Clin Electrophysiol Date: 2000-07 Impact factor: 1.976
Authors: B M Psaty; T A Manolio; L H Kuller; R A Kronmal; M Cushman; L P Fried; R White; C D Furberg; P M Rautaharju Journal: Circulation Date: 1997-10-07 Impact factor: 29.690
Authors: Jared W Magnani; Faye L Lopez; Elsayed Z Soliman; Richard F Maclehose; Richard S Crow; Alvaro Alonso Journal: Obesity (Silver Spring) Date: 2011-04-07 Impact factor: 5.002
Authors: David Conen; Usha B Tedrow; Bruce A Koplan; Robert J Glynn; Julie E Buring; Christine M Albert Journal: Circulation Date: 2009-04-13 Impact factor: 29.690
Authors: Elsayed Z Soliman; Akm F Rahman; Zhu-Ming Zhang; Carlos J Rodriguez; Tara I Chang; Jeffrey T Bates; Lama Ghazi; Joseph L Blackshear; Michel Chonchol; Lawrence J Fine; Walter T Ambrosius; Cora E Lewis Journal: Hypertension Date: 2020-05-04 Impact factor: 10.190
Authors: Aditya Bhat; Shaun Khanna; Henry H L Chen; Arnav Gupta; Gary C H Gan; A Robert Denniss; C Raina MacIntyre; Timothy C Tan Journal: Circ Cardiovasc Qual Outcomes Date: 2021-03-05
Authors: Lin Y Chen; Maarten J G Leening; Faye L Norby; Nicholas S Roetker; Albert Hofman; Oscar H Franco; Wei Pan; Joseph F Polak; Jacqueline C M Witteman; Richard A Kronmal; Aaron R Folsom; Saman Nazarian; Bruno H Stricker; Susan R Heckbert; Alvaro Alonso Journal: J Am Heart Assoc Date: 2016-05-20 Impact factor: 5.501
Authors: Dana Prídavková; Matej Samoš; Tomáš Bolek; Ingrid Škorňová; Jana Žolková; Peter Kubisz; Ján Staško; Marián Mokáň Journal: J Diabetes Res Date: 2019-12-06 Impact factor: 4.011
Authors: Matthew C Hyman; Michael G Levin; Dipender Gill; Venexia M Walker; Marios K Georgakis; Neil M Davies; Francis E Marchlinski; Scott M Damrauer Journal: Hypertension Date: 2021-01-04 Impact factor: 10.190